News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|March 31, 2011

Featured Supplement

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Ensitrelvir now available in US for COVID-19 postexposure prophylaxis | Image Credit: © Production Perig - stock.adobe.com

Ensitrelvir now available in US for COVID-19 postexposure prophylaxis

ByContemporary Pediatrics Staff

July 28th 2026

FDA clears pediatric Patient State Index for Masimo SedLine sedation monitoring

FDA clears pediatric Patient State Index for Masimo SedLine sedation monitoring

ByContemporary Pediatrics Staff

July 28th 2026

Omalizumab outperforms multiallergen oral immunotherapy in multifood allergy trial | Image Credit: © Graphicroyalty - stock.adobe.com.

Omalizumab outperforms multiallergen oral immunotherapy in multifood allergy trial

ByMorgan Ebert, Executive Editor

July 27th 2026

Garadacimab demonstrates positive results in phase 3b trial for pediatric HAE prophylaxis | Image Credit: © Gorodenkoff - stock.adobe.com.

Garadacimab demonstrates positive results in phase 3b trial for pediatric HAE prophylaxis

ByContemporary Pediatrics Staff

July 27th 2026

FDA approves centanafadine for ADHD in children, adolescents, and adults

FDA approves centanafadine for ADHD in children, adolescents, and adults

ByMorgan Ebert, Executive Editor

July 27th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA approves centanafadine for ADHD in children, adolescents, and adults

Omalizumab outperforms multiallergen oral immunotherapy in multifood allergy trial

Garadacimab demonstrates positive results in phase 3b trial for pediatric HAE prophylaxis

Pooled phase 3 data show early, consistent tapinarof cream responses across pediatric age groups in AD

US measles cases surpass 2025 total, hit highest level since 1991